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Abstract
Plasmodium vivax remains an important cause of malaria in South America and the Asia-
Pacific. Naturally acquired antibody responses against multiple P. vivax proteins have been
described in numerous countries, however, direct comparison of these responses has been
difficult with different methodologies employed. We measured antibody responses against
307 P. vivax proteins at the time of P. vivax infection, and at 2–3 later time-points in three
countries. We observed that seropositivity rates at the time of infection were highest in Thai-
land, followed by Brazil then PNG, reflecting the level of antigenic input. The majority of
sero-reactive antigens in all sites induced short-lived antibody responses with estimated
half-lives of less than 6 months, although there was a trend towards longer-lived responses
in PNG children. Despite these differences, IgG seropositivity rates, magnitude and longev-
ity were highly and significantly rank-correlated between the different regions, suggesting
such features are reflective of the individual protein.
Author summary
In the pursuit of eliminating all species of malaria, Plasmodium vivax presents one of the
most substantial challenges, particularly in countries in Asia, the Western-Pacific and
South America. This is primarily due to the ability of P. vivax to cause relapse infections
months to years after the initial infectious bite. In areas with low levels of malaria trans-
mission, serology has become an increasingly useful tool for surveillance, as anti-
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Plasmodium antibodies can be detected in individuals long after blood-stage parasites
have cleared. In this study, we provide a detailed characterisation of the antibody response
generated following P. vivax infection by measuring antibodies to over 300 P. vivax anti-
gens in three different populations in Thailand, Brazil and Papua New Guinea. The indi-
viduals in these populations were followed for up to nine months allowing us to estimate
the rate at which antibodies decay over time. This improved understanding of the magni-
tude and dynamics of the antibody response, validated in multiple populations, will con-
tribute to the development of serological surveillance tools needed for enhanced control
and elimination of P. vivax.
Introduction
Plasmodium vivax is the most geographically widespread of the Plasmodium spp. causing
malaria in humans, and accounts for the majority of cases outside Africa [1]. The leaders of
Central American and East Asian countries have declared their intention for elimination of
malaria within their regions by 2025 and 2030 [2, 3], respectively. Interrupting P. vivax trans-
mission may require the development of an effective vaccine and improved surveillance sys-
tems (due to the high proportion of sub-microscopic P. vivax infections [4] and the presence
of currently undetectable hypnozoites) [5]. Both objectives require a better understanding of
naturally induced immune responses, in particular antibody responses, following infection.
Protective immunity against clinical episodes of P. vivax malaria is acquired more rapidly
than immunity against P. falciparum [6, 7]. As a consequence, the burden of clinical P. vivax
disease falls predominantly on very young children, whilst infected adults are often asymptom-
atic [8–10]. Immunity against clinical symptoms is thought to be dependent on the develop-
ment of P. vivax-specific antibody responses [11, 12]. The prevalence of P. vivax-specific
antibody responses within endemic populations increases with age [13], and antibody levels
are generally higher in individuals with current P. vivax infections [14]. The parasite expresses
more than 5000 proteins throughout its lifecycle [15], and through the use of large-scale
screening platforms such as protein microarrays [16], an increasing number of these proteins
have been assessed for their immunogenicity in naturally exposed populations. These studies,
assessing antibody responses to over 1900 P. vivax proteins, have indicated that up to 50% of
such proteins are sero-reactive in individuals from malaria endemic areas [11]. Furthermore,
they have demonstrated that asymptomatic individuals have a greater breadth of response
[11], that reactive proteins are more likely to be encoded by genes with high single nucleotide
polymorphism diversity (potentially signifying positive immune selection) [17], and that the
majority of highly reactive proteins have predicted transmembrane domains and signal pep-
tides (SP) (signifying secreted or membrane-bound proteins) [18].
Whilst naturally acquired antibody responses have been assessed against multiple P. vivax
proteins in individuals from numerous geographic regions, it has been difficult to directly
compare these responses due to the different protein expression and antibody measurement
systems used. For example, whilst Finney and colleagues reported a greater breadth of anti-
body response in asymptomatic individuals in PNG compared to febrile patients [11], as noted
above, the opposite was later reported in Thailand [13] and no difference was identified in
India [19]. This could be due to the different geographic region and transmission intensity of
the study sites, or due to the use of different P. vivax protein microarrays encompassing differ-
ent sets of proteins.
Naturally acquired P. vivax antibody responses
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In this study we performed a direct comparison of naturally acquired antibody responses in
three different geographic regions: Brazil (very low transmission), Thailand (low transmission)
and PNG (moderate transmission). In these settings, we measured antibodies at 2–3 time-
points following P. vivax infection (in the absence of detectable recurrent infections), to a
panel of 307 P. vivax proteins. All samples were measured using the same platform (AlphaSc-
reen assay), with the same data analysis pipeline applied. We found that antibody positivity,
magnitude and longevity were highly and significantly correlated between the three study
sites; however, in general, antibody longevity was better maintained in PNG where individuals
have had greater past exposure to the parasite. Our study provides important new insights into
the generation and maintenance of P. vivax-specific antibody responses and how these factors
differ in regions of varying transmission intensity.
Methods
Ethics statement
The relevant local ethics committees approved all field studies, and the Human Research Ethics
Committee at WEHI approved samples for use in Melbourne (#14/02). The PNG study received
ethical clearance from the PNG Institute of Medical Research Institutional Review Board
(0908), the PNG Medical Advisory Committee (09.11), and the Ethics Committee of Basel (237/
11). This study was also retrospectively registered at ClinicalTrials.gov (NCT02143934). The
Thai study was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol
University, Thailand (MUTM 2014-025-01 and 02). The Brazilian study was approved by the
Ethics Review Board of the Fundac¸ão de Medicina Tropical Dr. Heitor Vieira Dourado
(FMT-HVD) (957.875/2014). All patients gave informed written consent or assent. For chil-
dren, informed written consent was provided by their parents.
Study sites
Three different study sites were used: Maprik District, East Sepik Province, Papua New Guinea
(PNG); Tha Song Yang District, Tak Province, Thailand; and Manaus, Brazil. A sub-set of
enrolled volunteers, where the probability of reinfection during the study period was low (in
order to accurately determine antibody longevity), was included in the present study as
described below.
The longitudinal study in PNG was conducted from August 2009 to May 2010, as described
[20]. In brief, 524 children aged 5–10 years were enrolled and block randomised to receive 20
days of directly observed therapy (DOT) of chloroquine, arthemeter-lumefrantrine with either
a placebo or primaquine. Children were subsequently monitored every 2 weeks for 8 months
to detect any signs or symptoms of infection, with finger-prick blood samples taken every 2
weeks for 12 weeks, then every 4 weeks for the remaining period. Blood samples were analysed
by light microscopy and qPCR for the presence of blood-stage parasites and plasma stored for
antibody measurements. A sub-set of 31 children with P. vivax infections at enrolment and no
evidence of reinfection during follow-up, with not more than one missed sample, were selected
for inclusion in the present study (all 31 received primaquine treatment). Plasma samples
from 0, 3 and 5 months were used.
The longitudinal study in Thailand was conducted from April 2014 to September 2015, as
described [21]. Briefly, 57 symptomatic P. vivax patients were enrolled from either the Tha
Song Yang malaria clinic or hospital. Patients were treated with chloroquine (25 mg base/kg
body weight, administered over 3 days) and primaquine (15 mg daily, for 14 days) under
DOT. Volunteers were followed for 9-months after enrolment, with finger-prick blood sam-
ples collected at enrolment and week 1, then every 2 weeks for 6 months, then every month
Naturally acquired P. vivax antibody responses
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005888 September 11, 2017 3 / 15
until the end of the study. All blood samples were analysed by both light microscopy and
qPCR for the presence of blood-stage parasites as per the PNG cohort, and plasma separated
and stored. A sub-set of volunteers, n = 32, were selected for use in the current study. These
volunteers had no detectable recurrent infections during 9-months follow-up, and were the
first to complete follow-up. Plasma samples from 0, 3, 6 and 9 months were used.
The longitudinal study in Brazil followed the same format as in Thailand. The study was
conducted from May 2014 to May 2015. 91 malaria patients at Fundac¸ão de Medicina Tropical
Doutor Heitor Vieira Dourado in Manaus aged between 7 and 70 years were enrolled. In-
dividuals with G6PD deficiency or chronic diseases were not enrolled. Patients were treated
according to the guidelines of the Brazilian Ministry of Health (3 days chloroquine, 7 days pri-
maquine). Follow-up intervals with finger-prick blood sample collection were as in the Thai
study. A sub-set of volunteers, n = 33, who had no detectable recurrent infections during
9-months follow-up, were selected for use in the antigen discovery project. Plasma samples
from 0, 3, 6 and 9 months were used.
Antigen selection
This study utilized a panel of 307 P. vivax protein fragments produced using a wheat germ cell-
free protein expression (WGCF) system. This panel of protein fragments includes well-known
P. vivax proteins such as potential vaccine candidates (i.e. merozoite surface protein 1 (MSP1),
apical membrane antigen 1 (AMA1), circumsporozoite protein (CSP)), orthologs of immuno-
genic P. falciparum proteins and proteins with a predicted SP and/or 1–3 transmembrane
domains (TM), and expands upon our previously published panel [22]. Fig 1 demonstrates key
features of these P. vivax proteins (annotation and expression-stage). Approximately 70% con-
tained a predicted SP, 50% at least one TM and 10% a GPI-anchor. All protein-specific informa-
tion was obtained from the Plasmodium Genomics Resource (PlasmoDB: http://plasmodb.org/
plasmo/) release 25.
WGCF protein synthesis
The recombinant proteins were expressed without codon optimization using the WGCF sys-
tem as previously described [23] with slight modifications. Briefly, the genes were amplified by
PCR and cloned into the pEU_E01 expression vector with N-terminal His-bls tag (CellFree
Sciences, Matsuyama, Japan). P. vivax genes were obtained either from parent clones [22],
using SAL-1 cDNA, or commercially synthesized from Genscript (Japan). DNA template for
WGCF was prepared from the plasmids by PCR with a forward primer (spu; 5-GCGTAGC
ATTTAGGTGACACT-3), and a reverse primer (pbsa1143; 5-GCTCACATGTTCTTTCCT
GC-3). WGCF synthesis of the P. vivax protein library was based on the previously described
bilayer diffusion system [24]. For biotinylation of proteins, 500 nM D-biotin (Nacalai Tesque,
Kyoto, Japan) was added to both the translation and substrate layers. Crude WGCF expressed
BirA (1 μl) was added to the translation layer. In vitro transcription and cell-free protein syn-
thesis for the P. vivax protein library were carried out using the GenDecoder 1000 robotic
synthesizer (CellFree Sciences) [25, 26]. Based on previous studies, the WGCF system can
synthesize biotinylated plasmodial protein ranging from 0.3 μg/mL to 26.5 μg/mL [27,28].
Expression of the proteins was confirmed by western blotting using HRP-conjugated stre-
ptavidin. Proteins were preferably expressed as full-length proteins, to ensure that any
possible antibody recognition site was covered; however, for very large proteins, multiple
fragments were expressed that together cover the entire protein. The panel included 263
unique proteins.
Naturally acquired P. vivax antibody responses
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005888 September 11, 2017 4 / 15
AlphaScreen assay
The AlphaScreen assay was performed following the manufacturer’s instructions (PerkinElmer
Life and Analytical Sciences, Boston, MA) as previously reported [27,28], with slight modifica-
tions. The protocol was automated by use of the JANUS Automated Workstation (PerkinEl-
mer Life and Analytical Science, Boston, MA). Reactions were carried out in 25 μl of reaction
volume per well in 384-well OptiPlate microtiter plates (PerkinElmer). First, 0.1 μl of the trans-
lation mixture containing a recombinant P. vivax biotinylated protein was diluted 50-fold
(5 μl), mixed with 10 μl of 4000-fold diluted plasma in reaction buffer (100 mM Tris-HCL
[pH 8.0], 0.01% [v/v] Tween-20 and 0.1% [w/v] bovine serum albumin), and incubated for
30 min at 26˚C to form an antigen-antibody complex. Subsequently, a 10 μl suspension of
streptavidin-coated donor-beads and acceptor-beads (PerkinElmer) conjugated with protein
G (Thermo Scientific, Waltham, MA) in the reaction buffer was added to a final concentration
of 12 μg/ml of both beads. The translation mixture was diluted 250 times, thus final concentra-
tion of biotinylated proteins ranged between approximately 1.2 ng/mL and 106 ng/mL. The
mixture was incubated at 26˚C for one hour in the dark to allow the donor and acceptor-beads
to optimally bind to biotin and human IgG, respectively. Upon illumination of this complex, a
luminescence signal at 620 nm was detected by the EnVision plate reader (PerkinElmer) and
the result was expressed as AlphaScreen counts. Each assay plate contained a standard curve of
total biotinylated rabbit IgG. This enabled standardisation between plates using a 5-paramater
logistic standard curve. All samples from Thailand and Brazil were run in triplicate, whilst
Fig 1. Characteristics of the 307 P. vivax proteins in the AlphaScreen assay. (A) Annotation was
determined by PlasmoDB release 25. MSPs: merozoite surface proteins or paralogs, ETRAMPs: early
transcribed membrane proteins, RBPs: reticulocyte binding proteins or precursors, LISPs: liver-specific
proteins, VIRs: variable surface proteins. (B) Expression stage was also determined by PlasmoDB release
25.
https://doi.org/10.1371/journal.pntd.0005888.g001
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those from PNG were run only once. Reading the plates was conducted in a randomized man-
ner to avoid biases.
The immunogenicity of each protein was assessed in two ways. Firstly by calculating the
geometric mean titre (GMT), and secondly through seropositivity–the proportion of samples
above a given threshold. The seropositivity cut-off was set at the limit of detection of the assay,
taken as half the lowest non-negative value from each of the three sites [24]. Proteins were
defined as reactive if more than 10% of the volunteers had levels above the seropositivity cut-
off at the baseline measurement (time of P. vivax infection).
Statistical modelling and analysis
All data manipulation and statistical analyses were performed in R version 3.2.3 [29]. Antibody
longevity was estimated using data from three or four time-points (0, 3 and 5 months in PNG;
0, 3, 6 and 9 months in Thailand and Brazil). A linear mixed effects model was used to estimate
the antibody half-life; using the lme4 [30] package in R. We assume that antibody titres decay
exponentially, equivalent to a linear reduction in log antibody titre over time. Denote Aijk to be
the antibody titre to antigen j in participant i at time tk which can therefore be described by the
following linear model:
logðAijkÞ  ðlogða0j Þ þ logðaijÞÞ þ ðr
0
j þ rijÞtk þ εj
logðaijÞ  Nð0; sA;jÞ
logðrijÞ  Nð0; sr;jÞ
εj  Nð0; sm;jÞ
where a0j is the geometric mean titre (GMT) at the time of infection; log(αij) is a random effect
accounting for the difference between participant i’s initial antibody titre and the population-
level GMT; r0j is the average rate of decay of antigen j in the population; rij is a random effect
for the difference between the decay rate of individual j with the population-level average; and
εj is a Normally distributed error term.
The model was only fitted to individuals who were seropositive at baseline. This model also
generated an estimate of the total variation in the data (arising from initial antibody level mea-
sured, the rate of antibody decay and the measurement error). Correlations between the three
cohorts were performed using the Spearman’s rank correlation coefficient.
Results
Volunteer characteristics
Plasma samples were utilised from three studies in different geographic regions, with slightly
different study designs. PNG included only children aged 5–10 years, whilst Brazil and Thai-
land included volunteers of all ages. Furthermore, all Thai and Brazilian volunteers were
enrolled following symptomatic infection, whilst all included PNG children had asymptomatic
infections. This resulted in significantly higher antigenic inputs in the Thai and Brazilian vol-
unteers compared to PNG children (p<0.0001, Kruskal-Wallis test with Dunn’s multiple com-
parisons test) (Table 1).
Comparison of seropositivity to 307 P. vivax proteins between three
different geographic regions
Reactivity was defined as more than 10% of the volunteers above the seropositivity cut-off,
with the results at baseline (time of P. vivax infection) used for this analysis. Of the 307 P.
Naturally acquired P. vivax antibody responses
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vivax proteins assessed, 302 were considered reactive in Thailand, 273 in Brazil and 236 in
PNG, with the population level breadth therefore highest in Thailand. All proteins considered
reactive in Brazil and PNG were also considered reactive in Thailand. There were 3 proteins
considered reactive in PNG and not Brazil (all with low levels of seropositivity, less than 30%),
29 proteins reactive in Thailand and not Brazil (seropositivity less than 35%), 40 proteins reac-
tive in Brazil and not PNG (less than 50% seropositivity), and 65 proteins reactive in Thailand
and not PNG. The majority of the reactive proteins identified in Thailand that were not
observed in PNG had less than 50% seropositivity at the time of infection, however there were
6 exceptions: PVX_082690 (MSP7), PVX_092995 (Pv-fam-a), PVX_079980 (hypothetical pro-
tein), PVX_110945 (hypothetical protein) and PVX_099900 (unspecified product).
Overall, there was a strong correlation between seropositivity rates at baseline for the over-
lapping reactive antigens between the three cohorts (Thailand v Brazil, r = 0.95; Thailand v
PNG, r = 0.89; Brazil v PNG, r = 0.88; all p<0.0001) (Fig 2). There were two outliers when
comparing Thailand and PNG: MSP1-19 (PVX_099980, fragment covering 4918–5187 base
pairs) and MSP5 (PVX_003770) (Fig 2B). Both these proteins induced high levels of seroposi-
tivity at the time of P. vivax infection in Thailand (92% and 94%, respectively), but low levels
in PNG (16% and 32%, respectively). We also measured IgG responses against another con-
struct of MSP1-19, base pairs 4863–5187, and responses were similarly higher in Thailand
(95%) compared to PNG (65%), although the difference was not as large. There were also two
proteins where seropositivity levels were high in PNG (more than 80%), but relatively low in
Brazil (less than 30%): PVX_100670 (aspartyl protease, putative) and PVX_097930 (a hypo-
thetical protein) (Fig 2C).
On an individual level, the breadth of the antibody response (that is, the number of antigens
an individual was seropositive for) was slightly higher in Thailand and PNG compared to
Table 1. Volunteer characteristics.
Brazil (n = 33) Thailand (n = 32) PNG (n = 31)
Epidemiologic overview
Age, average (range) 36 years (16–56) 29 years (7–71) 8 years (5–10)
Sex, percentage male 79% 56% 55%
qPCR Pv prevalence
(population-level)
5% 11.4% 47%
Study design
Data collected Apr 2014 –Sep 2015
(symptomatic)
May 2014 –May 2015
(symptomatic)
Aug 2009 –May 2010 (asymptomatic)
Treatment DOT CQ (3 days) + 15 mg PQ
(7 days)
DOT CQ (3 days) +
15 mg PQ (14 days)
DOT CQ + AL (3 days) + 0.5 mg/kg PQ
(20 days)
Samples used 0, 3, 6, 9 month plasma 0, 3, 6, 9 month plasma 0, 3, 5 month plasma
Results overview
Mean breadth*
+ve antigen per person
160/307 211/307 175/307
Mean breadth*
+ve persons per antigen
17/33 22/32 18/31
Geometric mean titre*
median (range)
0.02 (8.3x10-5, 299) 0.18 (1.8x10-4, 202) 0.22 (1.7x10-5, 417)
Proportion of short-lived antibodies (half-
life < 6 months)
88% 79% 59%
QMAL copies/μL (range) 1.18x105 (229–5.12x105) 1.62x106 (4.93x104-6.69x106) 10 (0.002–83)
*Measured at first time-point. QMAL performed as previously described [41].
https://doi.org/10.1371/journal.pntd.0005888.t001
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Brazil, at the time of P. vivax infection (Fig 3). The median number of antigens an individual
was seropositive for was 202 in Thailand, 173 in PNG and 151 in Brazil. There was a statisti-
cally significant difference between the three sites (p = 0.0004, Kruskal-Wallis test).
Fig 2. Correlation between seropositivity rates for antigens identified as reactive in multiple cohorts. (A) Thailand v Brazil, (B) Thailand v
PNG and (C) Brazil v PNG. Spearman correlation coefficients, r, are shown. A number of proteins with highly different seropositivity rates between
two sites are marked.
https://doi.org/10.1371/journal.pntd.0005888.g002
Fig 3. Breadth of the antibody response per person per cohort, at the time of P. vivax infection. The
number of antigens each individual was seropositive for is shown, with box-plots indicating the median and
ranges for each cohort site. Statistical difference was assessed using the Kruskal-Wallis test (p = 0.0004);
after adjustment for multiple comparisons with Dunn’s test, p = 0.0002 between Brazil and Thailand only.
https://doi.org/10.1371/journal.pntd.0005888.g003
Naturally acquired P. vivax antibody responses
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Comparison of antibody magnitude to reactive proteins between three
different geographic regions
In the AlphaScreen assay, the amount of protein used is not consistent between different pro-
teins. Therefore, the absolute magnitude of the antibody response measured cannot be com-
pared across proteins. However, the magnitude can be compared between individuals or
populations for the same proteins. The geometric mean antibody level was determined for
each protein for each study site, at the time of P. vivax infection. This value was then correlated
between different sites; for the reactive antigens in common at baseline, the geometric mean
was significantly correlated between all three cohorts (Thailand v Brazil, r = 0.96; Thailand v
PNG, r = 0.90; Brazil v PNG, r = 0.90; all p<0.0001) (Fig 4). Overall, slightly higher mean anti-
body levels were measured in PNG compared to both Brazil and Thailand.
Comparison of antibody longevity to reactive proteins in three different
geographic regions
Antibody responses to the 307 P. vivax proteins were measured at multiple time-points; this
made it possible to estimate the antibody longevity for the reactive proteins in each cohort (Fig
5). Antibody responses with an estimated half-life of less than 6 months (180 days) were con-
sidered short-lived, whereas those more than 6 months were considered long-lived. The
majority of reactive antigens in all cohorts were considered short-lived, with the greatest pro-
portion in Brazil (88%), followed by Thailand (79%), then PNG (59%). The range of estimated
antibody half-lives in each cohort were as follows: 12–445 days in Brazil, 18–713 days in Thai-
land and 10–70,000 days in PNG. With 5 to 9 months of longitudinal data, there is limited sta-
tistical power to estimate very long half-lives, and hence a half-life of greater than 1,000 days is
usually indistinguishable from no change in antibody titres over time. Overall, there was a
strong correlation between estimated antibody longevity estimates for reactive proteins, when
proteins with negative antibody half-life estimates were excluded (Thailand v Brazil, r = 0.92,
n = 273 proteins; Thailand v PNG, r = 0.87, n = 219 proteins; Brazil v PNG, r = 0.86, n = 216
proteins; all p<0.0001) (Fig 6).
Fig 4. Correlation between the geometric mean antibody responses for antigens identified as reactive in multiple cohorts, at the time of P.
vivax infection. (A) Thailand v Brazil, (B) Thailand v PNG and (C) Brazil v PNG. Spearman correlation coefficients, r, are shown.
https://doi.org/10.1371/journal.pntd.0005888.g004
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Concerning a number of well-recognised P. vivax antigens mentioned above, IgG responses
to MSP1-19 and MSP5 were estimated to be exceptionally short-lived in all three cohorts, with
half-lives of 16–41 days and 20–57 days, respectively. Responses to MSP1-42 were similarly
short-lived in Brazil and Thailand (half-lives of 58–97 days) but were long-lived in PNG (esti-
mated IgG half-life of almost 3 years).
Discussion
In this study we have compared naturally acquired IgG antibody responses to over 300 P.
vivax protein constructs in three geographically different locations with varying levels of P.
vivax transmission. Manaus, Brazil and Tak, Thailand are both low-transmission regions (with
Fig 5. Example of antibody longevity to three different proteins for three randomly selected participants from each of the three study sites. The
first row provides an example of a typical protein inducing a short-lived antibody kinetic profile; the middle row provides an example of a moderate-lived
profile; the final row provides an example of an exceptionally long-lived profile. Each plot provides data from three individuals, who are differentially colour
coded. The dashed line denotes the sero-positivity cut-off.
https://doi.org/10.1371/journal.pntd.0005888.g005
Naturally acquired P. vivax antibody responses
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approximately 0–5% and 1–11% of individuals infected in recent surveys, respectively [13,21,
31]). The participants from PNG were part of a larger study where a PCR prevalence of 47%
was measured at baseline [20]. At the time of P. vivax infection we observed that a high pro-
portion of the 307 P. vivax proteins were reactive (77–98%). This is higher than previous
reports using large-scale screening platforms, where sero-reactivity has ranged from 14–50%
in P. vivax patients [11, 17, 22], likely due both to our down-selection of proteins predicted to
be immunogenic and our definition of seropositivity (based on the limit of detection of the
assay, rather than unexposed controls). We observed higher numbers of sero-reactive proteins
in Thailand and Brazil compared to PNG; the volunteers in Thailand and Brazil who had
symptomatic infections also had significantly higher parasite densities than the asymptomatic
children in PNG, signifying that antigenic input has a significant effect on the breadth of the
antibody response. Similarly, on an individual level, Thai volunteers showed a trend towards a
greater breadth of response compared to Brazil and PNG. This pattern of greater breadth of
response in individuals with higher parasite densities [11], and following symptomatic versus
asymptomatic infections [13], has been reported previously. As asymptomatic infections are
becoming increasingly recognised in low-transmission regions such as Thailand [13], it would
be valuable to compare the breadth of response at the time of asymptomatic P. vivax infection
in Thailand, or a similar low-transmission region, to that in PNG.
The additional proteins identified as sero-reactive in Thailand and Brazil compared to PNG
had only low levels of seropositivity amongst the 32–33 individuals at time of infection (i.e.
between 10–50%), except for a small number of proteins in the Thai individuals including one
Pv-fam-a protein (PVX_092995) and MSP7 (PVX_082690). In general, there was good corre-
lation in levels of seropositivity to all antigens considered reactive in multiple cohorts. Two
key exceptions were observed: high levels of seropositivity in Thai individuals to MSP1-19
(fragment covering base pairs 4918–5187) and MSP5 (92% and 94%, respectively), with only
low-levels of seropositivity observed in the PNG children (16% and 32%, respectively). MSP1
and MSP5 are both blood-stage antigens considered potential vaccine candidates, based pri-
marily on their location on the merozoite surface and pre-clinical studies of the P. falciparum
orthologs [32, 33]. MSP1 first exists as a 42 kDa protein attached to the surface of merozoites
via a GPI anchor; following invasion of RBCs the protein is cleaved into two products, of 33
kDa and 19 kDa, with the 19 kDa fragment remaining on the merozoite surface [34]. We
observed 100% seropositivity in all cohorts to the MSP1-42 fragment. Not a lot is known about
Fig 6. Correlation between the antibody longevity (estimated half-life) for antigens identified as reactive in multiple cohorts. Only antigens
with positive half-life estimates were included. (A) Thailand v Brazil, (B) Thailand v PNG and (C) Brazil vs. PNG. Spearman correlation coefficients, r, are
shown. Data are plotted on log scales to aid visualisation.
https://doi.org/10.1371/journal.pntd.0005888.g006
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IgG responses to MSP5 [33], but responses to MSP1-19 are frequently observed in endemic
regions [35], and are known to be short-lived [36]. We observed short-lived responses to both
MSP1-19 and MSP5 in all three study sites. In agreement with our current finding, higher IgG
titres to MSP1-19 have been observed in sporadically rather than chronically exposed volun-
teers in an endemic region of Brazil [37]; together this suggests that in chronically exposed
individuals, such as PNG children, MSP1-19 and MSP5 may be able to escape recognition of
the humoral immune system or that such low-density infections are unable to adequately
boost the IgG response. However, it is important to note that we observed moderate levels of
seropositivity in PNG children to a second construct of MSP1-19 (covering base pairs 4863–
5187), and another study has also found prevalent IgG responses to MSP1-19 in younger PNG
children [38]. Our current finding therefore warrants further investigation with a larger sam-
ple size to clarify these results.
The majority of previous studies that have assessed IgG antibody responses to a large panel
of P. vivax proteins have been cross-sectional in design; whilst this provides useful information
on antibody acquisition and immunogenicity, it fails to provide detailed information regard-
ing antibody longevity. In this study we assessed antibody responses at 2–3 further time points
following P. vivax infection, in the absence of detectable recurrent infections, to investigate
antibody decay. We observed that in our two low-transmission study sites, Thailand and Bra-
zil, most antigens had relatively short-lived IgG responses, with estimated antibody half-lives
of less than 6 months. It is important to note that this was not observed for all proteins, with
some exhibiting exceptionally long-lived IgG profiles with half-lives up to 700 days, and we are
currently investigating the mechanisms behind such differential responses. Conversely, in the
PNG children who had a high level of past, lifetime exposure [6], 41% of proteins induced
long-lived IgG responses with estimated half-lives of more than 6 months, and there was a
trend towards longer-lived responses to many proteins in these children compared to individ-
uals from Thailand and Brazil. This suggests that whilst the breadth of response may be depen-
dent upon the level of antigenic input, IgG responses can be long-lived to many proteins if
there has been sufficient past levels of exposure within a region. Together, this provides further
evidence that IgG responses to P. vivax proteins can be long-lived, dependent on the transmis-
sion setting and specific protein, which is in contrast to most reported studies of IgG longevity
against P. falciparum proteins, where responses are generally short-lived in the absence of
ongoing exposure [35, 39].
Despite these differences between study sites in terms of the breadth and longevity of the
IgG response, there was a highly significant rank-correlation between sites in terms of the pro-
portion of individuals seropositive to each antigen, the magnitude of the IgG response to each
antigen, and the estimated antibody half-life to each antigen. This suggests that despite the dif-
ferences due to parasite density and past exposure levels, immunogenicity and longevity are
ultimately characteristics specific to individual proteins. This feature is therefore highly prom-
ising for the use of IgG antibody responses as markers of exposure in multiple geographic
regions, if the transmission level and current infection status is taken into consideration.
An important consideration for future research is the impact of age on the IgG responses
observed; our current work has attributed differences in the PNG cohort to the higher level of
transmission within this region and lower antigenic input due to asymptomatic infection,
however the age of the volunteers could also have an effect. In addition, longitudinal studies of
individuals from low-transmission regions following asymptomatic P. vivax infections would
also be valuable to further support our hypotheses. Furthermore, the potential for cross-reac-
tivity of these P. vivax proteins with P. falciparum will become increasingly important in
regions where these species are co-endemic. The potential for cross-reactivity will be tested by
measuring responses in cohorts which are known to have P. falciparum but no P. vivax [40]. In
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summary, our study has utilised a panel of more than 300 P. vivax proteins, the majority of
which were immunogenic, to provide evidence for a number of key features relating to IgG
acquisition and longevity: that the individual and population-level breadth of IgG seropositiv-
ity is a function of antigenic input, whilst longevity is a function of the level of transmission
(and hence lifetime exposure to the parasite).
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